Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness

Slide: 10 of 35

Clinical Questions Addressed by the Comparative Effectiveness Review (2 of 2)

The comparative effectiveness review focused on the first-generation (FGAs) and second-generation (SGAs) antipsychotics used to treat adults (ages 18 to 64 years) with schizophrenia, schizophrenia-related psychoses, and bipolar disorder (all are approved indications). Clinical questions addressed by the comparative effectiveness review include:

  • Do FGAs and SGAs differ in medication-associated adverse effects and safety?
  • What is the comparative effectiveness of FGAs versus SGAs for outcomes other than core illness symptoms, such as relapse and remission rates, medication adherence, patient insight, health-related quality of life, and patient satisfaction?